Iovance Biotherapeutics, Inc.
IOVA
$6.98
$0.467.06%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 39.04% | -17.68% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 39.04% | -17.68% | |||
| Cost of Revenue | 2.58% | -1.42% | |||
| Gross Profit | 92.58% | -33.73% | |||
| SG&A Expenses | 0.83% | 7.00% | |||
| Depreciation & Amortization | 11.25% | -10.28% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.82% | -4.84% | |||
| Operating Income | 35.95% | -10.32% | |||
| Income Before Tax | 38.92% | -11.14% | |||
| Income Tax Expenses | -106.47% | -461.41% | |||
| Earnings from Continuing Operations | 40.14% | -9.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 40.14% | -9.93% | |||
| EBIT | 35.95% | -10.32% | |||
| EBITDA | 41.51% | -14.12% | |||
| EPS Basic | 44.36% | -6.90% | |||
| Normalized Basic EPS | 43.99% | -7.58% | |||
| EPS Diluted | 44.36% | -6.90% | |||
| Normalized Diluted EPS | 43.99% | -7.58% | |||
| Average Basic Shares Outstanding | 7.57% | 2.84% | |||
| Average Diluted Shares Outstanding | 7.57% | 2.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||